Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) – Pipeline Review, H2 2016’, provides in depth analysis on Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted pipeline therapeutics.

The report provides comprehensive information on the Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)

The report reviews Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics and enlists all their major and minor projects

The report assesses Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aileron Therapeutics, Inc.

CASI Pharmaceuticals Inc.

Cerulean Pharma, Inc.

Daiichi Sankyo Company, Limited

F. Hoffmann-La Roche Ltd.

InterMed Discovery GmbH

OncoImmune, Inc.

Peloton Therapeutics, Inc.

RXi Pharmaceuticals Corporation

Sorrento Therapeutics, Inc.

Transcriptogen Ltd

Vascular Biogenics Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) Overview 9

Therapeutics Development 10

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Products under Development by Stage of Development 10

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Products under Development by Therapy Area 11

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Products under Development by Indication 12

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Products under Development by Companies 16

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Products under Development by Universities/Institutes 19

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Assessment 21

Assessment by Monotherapy/Combination Products 21

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Companies Involved in Therapeutics Development 28

Aileron Therapeutics, Inc. 28

CASI Pharmaceuticals Inc. 29

Cerulean Pharma, Inc. 30

Daiichi Sankyo Company, Limited 31

F. Hoffmann-La Roche Ltd. 32

InterMed Discovery GmbH 33

OncoImmune, Inc. 34

Peloton Therapeutics, Inc. 35

RXi Pharmaceuticals Corporation 36

Sorrento Therapeutics, Inc. 37

Transcriptogen Ltd 38

Vascular Biogenics Ltd. 39

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Drug Profiles 40

A-503451A - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Antisense RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Oncology - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Antisense RNAi Oligonucleotide to Inhibit SOX4 and HIF-1 Alpha for Metastatic Ovarian Cancer - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ATSP-9172 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

BC-001 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

CASI-2ME2 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

CRLX-101 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Echinomycin - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

HS-1793 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

IMD-026259 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

KCN-1 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

MPT-0B098 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

RG-6061 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecule to Inhibit HIF-1 Alpha for Oncology - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

SR-16388 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

TR-764 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

TSG-1900 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

VB-411 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Dormant Projects 73

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Discontinued Products 77

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Featured News & Press Releases 78

Jul 19, 2016: Cerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer 78

Jun 22, 2016: Cerulean Announces Publication in Cancer Research 78

Jun 09, 2016: Cerulean Announces Manuscript Published in Annals of Oncology 79

May 19, 2016: Cerulean Announces Oral Presentation on Phase 1b results of CRLX101 at Gynecologic Oncology 2016 Conference 80

May 10, 2016: Cerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA 80

Apr 25, 2016: Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference 81

Apr 19, 2016: Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer 82

Mar 23, 2016: Cerulean Announces Publication Showing CRLX101 Localizes Selectively in Human Tumors, Sparing Adjacent Healthy Tissue 84

Mar 16, 2016: Cerulean Announces Data Presentation at the 2016 American Association for Cancer Research Annual Meeting 85

Nov 09, 2015: Cerulean Announces Data at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 87

Oct 27, 2015: Cerulean Announces Poster Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 88

Oct 19, 2015: Cerulean Announces First Patient Dosed in Clinical Trial to Evaluate Weekly Dosing Schedule with CRLX101 89

Oct 15, 2015: Cerulean Announces Completion of Enrollment of Randomized Phase 2 Trial of CRLX101 in Combination with Avastin in Relapsed Renal Cell Carcinoma 89

Sep 30, 2015: Cerulean Announces CRLX101 Advances to Second Stage of Phase 2 Clinical Trial of CRLX101 in Combination with Avastin in Relapsed Ovarian Cancer 90

Jul 21, 2015: Cerulean Announces First Patient Dosed in Phase 1b Trial of CRLX101 in Combination with Weekly Paclitaxel in Relapsed Ovarian Cancer 90

Appendix 92

Methodology 92

Coverage 92

Secondary Research 92

Primary Research 92

Expert Panel Validation 92

Contact Us 92

Disclaimer 93

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Products under Investigation by Universities/Institutes, H2 2016 20

Assessment by Monotherapy/Combination Products, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Pipeline by Aileron Therapeutics, Inc., H2 2016 28

Pipeline by CASI Pharmaceuticals Inc., H2 2016 29

Pipeline by Cerulean Pharma, Inc., H2 2016 30

Pipeline by Daiichi Sankyo Company, Limited, H2 2016 31

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 32

Pipeline by InterMed Discovery GmbH, H2 2016 33

Pipeline by OncoImmune, Inc., H2 2016 34

Pipeline by Peloton Therapeutics, Inc., H2 2016 35

Pipeline by RXi Pharmaceuticals Corporation, H2 2016 36

Pipeline by Sorrento Therapeutics, Inc., H2 2016 37

Pipeline by Transcriptogen Ltd, H2 2016 38

Pipeline by Vascular Biogenics Ltd., H2 2016 39

Dormant Projects, H2 2016 73

Dormant Projects (Contd..1), H2 2016 74

Dormant Projects (Contd..2), H2 2016 75

Dormant Projects (Contd..3), H2 2016 76

Discontinued Products, H2 2016 77

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports